Amylyx Pharmaceuticals

Nasdaq: AMLX · SEC EDGAR filings

Results on file1
Average 24h move+66.59%across 1 result with a complete 24h price
1 resultAmylyx Pharmaceuticals
Met endpoint

Avexitide

Phase 3 n=75 Post Bariatric Hypoglycemia

Amylyx Pharmaceuticals AMLX

24h stock move +66.59%

For information only. Not investment or medical advice. Prices are historical, from consolidated market data, and may contain errors. Always check the original source.